Warning: Dangerous Substance Detected in THC E-cigarette Users

Regulations by 2FIRSTS.ai
Apr.10.2024
Warning: Dangerous Substance Detected in THC E-cigarette Users
UK experts warn THC e-cigarette users may unknowingly inhale dangerous substance "zombie drug," sparking government action.

According to a report by BBC on April 10th, British experts have warned that individuals who use Tetrahydrocannabinol (THC) e-cigarettes may inhale a highly dangerous substance known as "zombie drug" (xylazine). The key concern is that this sedative is primarily used to induce sleep in large animals such as cows and horses, and can be deadly for humans.

 

So far, the black market "zombie drug" has most commonly been mixed with powerful opioids such as heroin or fentanyl.

 

Dr. Caroline Copeland of King's College London has reported that a new type of illegal "zombie drug" is entering the UK market. Their research has found that some pills being sold as codeine and diazepam, or Valium, also contain this "zombie drug.

 

The UK government has classified this drug as a Class C substance, alongside laughing gas, anabolic steroids, and benzodiazepines. This means that possession of this drug could result in a two-year prison sentence, while trafficking it could lead to a 14-year sentence.

 

According to reports, tetrahydrocannabinol (THC) is the main psychoactive ingredient in cannabis, and e-cigarettes containing THC are illegal in the UK. Cannabidiol (CBD) is another component of the cannabis plant, but it does not cause a high, and CBD oil (including e-cigarettes) is legally sold in the UK.

 

Experts say that people may not realize what they are actually buying; they may think they are purchasing an e-cigarette containing THC, but in reality, it may contain unexpectedly more substances.

 

A government spokesperson stated, "We are aware of the threat of 'zombie drugs' and are determined to protect the public from the dangers of this drug and other illicit synthetic drugs. In line with the recommendations of the Advisory Council on the Misuse of Drugs, we plan to classify 'zombie drugs' as Class C drugs."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
FEELM Releases Four Transparent Pod-Related Solutions for the TPD Market
FEELM Releases Four Transparent Pod-Related Solutions for the TPD Market
FEELM, a technology brand under Smoore, released four product solutions at an industry expo held in France, including OMNI POD MINI, OMNI POD MAX, TWINBREEZE, and CRYSBERG. The solutions are designed around TPD market needs and involve transparent pod design, leak-resistant structures, flavor performance, smart recognition, and different capacity configurations.
Apr.09 by 2FIRSTS.ai
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
China’s tobacco system has appointed a new top internal leader with a long background in public finance and taxation, drawing renewed attention to whether the country’s tobacco monopoly may enter a new phase of reform debate. The appointment itself does not signal a defined policy shift.But it places a veteran fiscal official at the center of a key state sector amid unresolved questions on tax reform, structure, and emerging tobacco products.
Mar.20
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.
May.09 by 2FIRSTS.ai